Latest news with #PEARL
Time of India
6 days ago
- Entertainment
- Time of India
NYT Connections #765 hints and answers for July 15, 2025: Today's puzzle twists categories like never before — can you master all four Connections?
NYT Connections July 15, 2025 hints and answers: Get today's full solution breakdown with categories- If you're playing today's NYT Connections for July 15, 2025 (#765) and finding it tricky to crack all four word groups, we've got you covered. This daily word puzzle from The New York Times continues to challenge players to spot subtle patterns and associations between seemingly random words. But if a few categories are keeping you stuck, don't worry—we'll walk you through today's hints, themes, and full answers with everything you need to solve it. What's NYT Connections and how does it work? The NYT Connections puzzle gives players a 4x4 grid of 16 words, asking them to group them into four sets of four. Each set shares a common link—sometimes obvious, other times quite abstract or based on wordplay. The challenge is to figure out what ties the words together. These links might be categories like tools, films, phrases, or synonyms. You get four chances to make incorrect guesses before the game ends. Categories are color-coded by difficulty: Yellow: Easy Green: Medium Blue: Hard Purple: Most difficult (often tricky or abstract) What are today's NYT Connections hints and themes? Here are your quick hints for July 15—ranked by difficulty level: Yellow group hint: What you'd see in Olympic gymnastics—think of apparatus Simone Biles uses. Green group hint: All about being forced out or removed from somewhere. Blue group hint: These are 2022 horror movies that spooked theaters. Purple group hint: Add 'horse' in front of these for some interesting compound terms. If you want to solve it on your own, try thinking in terms of categories like sports equipment, movie titles, and common compound phrases. Live Events What are the answers for NYT Connections on July 15, 2025? If you're ready for the full solution, here's the breakdown of all four correct groups: Yellow group – Gymnastics apparatus Words: BARS, BEAM, RINGS, VAULT These are all apparatuses used in gymnastics, especially in women's and men's artistic competitions. Think Olympics. Green group – Force to leave Words: BOOT, BOUNCE, EJECT, REMOVE Each of these words can mean to kick someone out —whether it's from a bar, a meeting, or a team. Blue group – Horror movies from 2022 Words: NOPE, PEARL, SCREAM, SMILE These were all horror films released in 2022 . Notably: Nope by Jordan Peele Pearl , a prequel to X Scream , the reboot sequel Smile , a viral horror hit Purple group – Horse ____ Words: FEATHERS, PLAY, POWER, SHOE When you put 'Horse' in front of each: Horsefeathers Horseplay Horsepower Horseshoe This was the most abstract group today and quite tricky. What makes today's NYT Connections puzzle difficult? Puzzle #765 balances a clean progression from easy to hard. The gymnastics group is straightforward, especially if you're familiar with Olympic sports. But the purple set, involving 'horse' compound words, leans heavily into linguistic creativity, making it the toughest. The horror movie group is challenging unless you're a fan of modern cinema or remember the 2022 film slate. And the green group can mislead with synonyms or similar-sounding terms—highlighting how red herrings are part of the strategy. How to get better at solving NYT Connections? If you're looking to improve your streak or finish faster, here are a few quick tips: Start with the obvious. Look for words that are concrete objects or direct actions. Say the words out loud. This helps spot phrases like 'Horsepower' or 'Boot out.' Hit the shuffle button. Sometimes rearranging the grid gives your brain a fresh perspective. Look for pop culture clues. If a word sounds like a movie title, it might be just that. 💡 Pro tip: NYT Connections often includes wordplay or trick phrases. It's not always about meaning—sometimes it's about how the words sound or pair with others. Today's NYT Connections puzzle The NYT Connections puzzle for July 15, 2025, is a perfect example of how the game blends language, culture, and lateral thinking. Whether you're a horror movie buff or a gymnastics fan, today's puzzle had something for everyone—but it also tested your mental flexibility, especially with the 'horse' wordplay. For more daily puzzle help, including Wordle #1487 and NYT Strands #499 , stay tuned. We publish daily hints and full solutions to keep your streak alive! FAQs: Q1: What are the NYT Connections July 15, 2025 categories? They're themed word groups from puzzle #765 that test logic, memory, and wordplay. Q2: Where can I find hints and answers for NYT Connections #765? Right here—you'll get clear, spoiler-friendly clues and full solutions for today's game.
Chicago Tribune
05-07-2025
- Health
- Chicago Tribune
Northwestern Medicine launches program for patients with obesity concerns who are planning a pregnancy
Northwestern Medicine has launched a program to help patients who have concerns related to obesity and are planning a pregnancy. Women with higher levels of body fat sometimes struggle to conceive and can face greater health risks during pregnancy. The PEARL program, which stands for Preconception and Early Assessment Care Rooted in Lifestyle Management, aims to help these patients have safe and healthy pregnancies. Dr. Christina Boots, a reproductive endocrinology and infertility specialist and one of the clinicians in the program, estimates that about one-third of her infertility patients struggle with obesity. 'There's many more beyond that, who maybe don't meet the criteria for obesity, but are struggling with overweight or insulin resistance and prediabetes or any other metabolic health dysfunction that could be optimized before we go forward,' she said. The PEARL program is designed to help patients with weight-driven concerns about any stage of pregnancy, from infertility to potential complications during delivery. It's open to patients with a BMI, or body mass index, above 27. BMI is calculated from a person's height-to-weight ratio that can give a quick estimate of total body fat. The Centers for Disease Control and Prevention reports the average American woman's height to be 5 feet, 3.5 inches; at this height, a patient would have to weigh 157 pounds or more to qualify for the PEARL clinic. 'There's so much weight bias and stigma that goes into weight, and there's a lot of stigma and bias and blame that goes into infertility as well,' Boots said. 'We just thought we could do a better job than what we were in terms of counseling women.' Boots said she and other physicians in the program have been unofficially working with patients on obesity concerns related to pregnancy for a few years. By making it an official program within Northwestern Medicine, clinicians are able to dedicate time to see these patients alongside their usual caseloads. 'We're just making sure that we're blocking out time so that there's always an opportunity for women to get in.' The program currently has four clinicians. Boots addresses how a higher BMI may affect fertility. Dr. Veronica Johnson, an internal medicine practitioner with a specialty in obesity medicine, primarily focuses on preconception weight loss. Drs. Jacqueline Hairston and Michelle Kominiarek, as the two maternal-fetal medicine specialists, address patients who are close to becoming or are already pregnant. Some patients are aiming to lower their BMIs in order to increase their fertility; others are aiming to manage BMI-related issues such as cholesterol, blood pressure and blood glucose to decrease risk before, during, or after pregnancy. 'The whole purpose of this is to address their concerns, and not to say, 'Hey, you need to lose a bunch of weight,'' Boots said. 'All the women in the program believe that there can be health at every size, and none of us believe that you must lose weight in order to get pregnant or to have a healthy pregnancy at all.' One of Johnson's patients, who declined to share her name because of the personal nature of her treatment, came to the clinic through an internal referral from her Northwestern OB-GYN. 'I knew that, even more than having a child, I wanted to be healthy, and I knew that I was at a weight that was completely unhealthy,' she said. 'I was at my largest weight that I had ever been in my life, and I knew I needed to do something about it.' Johnson's patient knew that she would likely have to go through in vitro fertilization because of her family history. IVF programs often have a maximum BMI limit around 40 or 50 — that's between 230 and 290 pounds at 5 feet 3.5 inches. When the patient first met with Johnson, her BMI was 58; with PEARL's help, she's reduced her BMI to 48 in less than a year. She began IVF in October, and is about to start her fourth cycle. 'It's mainly from an anesthesia perspective that that BMI threshold is there. It's not anything other than that, which is unfortunate, because we're trying to stay away from BMI, but then we're telling patients that you can't proceed with this procedure because your BMI is too high,' Johnson said. Egg retrieval for IVF is often done under 'twilight' anesthesia, where patients are not completely under. Alongside requiring higher dosages of anesthesia, Hairston explained that patients with higher BMIs may already have breathing issues, and in the event of an emergency, the clinic team may not be able to secure their airway. 'I have a couple patients who had a BMI at 55-60, and I've gotten them, over the last year and some change, to lose 70-80 pounds, where their BMI is now less than 50. And they're really excited, and now they're in the place where they're going to proceed with IVF,' Johnson said. While the PEARL program tries to emphasize lifestyle management before pharmaceutical intervention, sometimes using weight loss medication is the right choice. 'A lot of times, when patients come to see me, they're like, 'Well, I know how to eat, I know I should be exercising, and I've tried all those things, and it's really hard for me.' And that's when we need to think about other tools to kind of help them get to a healthier weight,' Johnson said. At the same time, the effects of weight loss medications on pregnancies are still unknown. These medications are expected to be used continuously, Hairston said, but since there is not enough knowledge of how these medications affect a fetus, patients are advised to stop using them at least two months before attempting to get pregnant, and to stop using them immediately if they test positive while on the medication. 'Typically for patients with obesity, the recommended weight gain in pregnancy is 11 to 20 pounds. But you can imagine, some of our patients may have lost more than that as a result of these medications,' Hairston said. When patients stop using many of these medications, there is often rebound weight gain; Hairston said that doctors are still discovering how this factors into pregnancy weight gain. Another concern the program hopes to address is the conflict between weight loss goals and the expected weight gain of pregnancy. Regardless of BMI, some weight gain is important for a safe pregnancy. That number is lower for patients with higher BMIs, but weight loss during pregnancy, especially in the third trimester, can adversely affect the baby. Even for a patient who became pregnant with a BMI between 18.5 and 25, which is considered healthy, expected pregnancy weight gain is likely to push them into the overweight category. 'I really think the goal of this program is to be more inclusive in the care of patients with a higher BMI, so that they don't feel like they are being excluded from the pregnancy conversation. And we're excited to meet anyone who wants to meet with us,' Hairston said.
Hindustan Times
23-06-2025
- Health
- Hindustan Times
Do longevity drugs work?
As elixirs of life go, long-term fasting is a surprising candidate. Yet it seems to work. Experiments on species from nematode worms to rhesus monkeys show that near-starvation prolongs lifespan. And, though no long-term experiment has been conducted to prove the same is true in Homo sapiens, short-term ones suggest similar physiological changes happen. PREMIUM Both rapamycin and metformin have drawn the attention of the 'live for ever' brigade because they inhibit what is known as the mTOR pathway (indeed, mTOR stands for 'mechanistic target of rapamycin')(Representational image) Mysteriously, however, most people are loth to trade three square meals a day in the here and now for the promise of a longer retirement, so the search has been on for chemical alternatives to fasting. Two molecules in particular have attracted attention: rapamycin, an immunosuppressant used to stop the rejection of transplanted kidneys, and metformin, an anti-diabetes drug. June 19th saw the publication of a paper summarising the evidence of their effectiveness in animals, compared with fasting. Both rapamycin and metformin have drawn the attention of the 'live for ever' brigade because they inhibit what is known as the mTOR pathway (indeed, mTOR stands for 'mechanistic target of rapamycin'). Overactivation of this in old age is associated with hallmarks of ageing such as inflammation. Conversely, fasting suppresses mTOR activity. That promotes autophagy, a phenomenon in which cells clear out their accumulated crud, which is reckoned lifespan-enhancing. Moreover, both substances also have the advantages of having undergone safety trials as part of approval for their on-label uses, and of being off-patent, and therefore cheap. Being off-patent, however, cuts both ways. It means commercial sponsors for human clinical trials are hard to find, since they cannot monopolise sales. As a result the Targeting Ageing with Metformin (TAME) trial, a proposal sponsored by the American Federation for Aging Research, a charity, and approved by the Food and Drug Administration in 2015, remains in abeyance for lack of funds. Rapamycin, by contrast, has been tested in what is known as the PEARL (Participatory Evaluation of Ageing with Rapamycin for Longevity) trial, which began in July 2020. But this found no strong evidence that it worked. Animal tests have proved more definitive. The new paper, published in Aging Cell by Edward Ivimey-Cook of Glasgow University and his colleagues, gathers all the vertebrate-trial evidence that the authors could find. This amounts to 167 studies on eight species, ranging from fish to monkeys. The answers seem clear-cut. To no one's surprise, calorie restriction works. So, to a pretty-much equal extent, does rapamycin. But metformin does not. That is a blow to those, their number unknown but probably amounting to thousands, who have twisted their doctors' arms to get an off-label prescription of it for life extension. But it is a boost to those who have opted for rapamycin. These include Vinod Khosla, one of Silicon Valley's best-known venture capitalists, and, until recently, Bryan Johnson, another Californian techie, who has made a second career out of his quest for immortality. Mr Johnson, however, dropped rapamycin in 2024 because of its side-effects (abnormal lipid and glucose levels, elevated heart rate and increased risk of skin infection). All of which is interesting. But for mere mortals who want a long and healthy life without the risk of rapamycin's side-effects the advice remains the same: eat wisely, drink moderately, exercise regularly, sleep well. And stub that cigarette out. Curious about the world? To enjoy our mind-expanding science coverage, sign up to Simply Science, our weekly subscriber-only newsletter.
Mint
21-06-2025
- Health
- Mint
Do longevity drugs work?
As elixirs of life go, long-term fasting is a surprising candidate. Yet it seems to work. Experiments on species from nematode worms to rhesus monkeys show that near-starvation prolongs lifespan. And, though no long-term experiment has been conducted to prove the same is true in Homo sapiens, short-term ones suggest similar physiological changes happen. Mysteriously, however, most people are loth to trade three square meals a day in the here and now for the promise of a longer retirement, so the search has been on for chemical alternatives to fasting. Two molecules in particular have attracted attention: rapamycin, an immunosuppressant used to stop the rejection of transplanted kidneys, and metformin, an anti-diabetes drug. June 19th saw the publication of a paper summarising the evidence of their effectiveness in animals, compared with fasting. Both rapamycin and metformin have drawn the attention of the 'live for ever" brigade because they inhibit what is known as the mTOR pathway (indeed, mTOR stands for 'mechanistic target of rapamycin"). Overactivation of this in old age is associated with hallmarks of ageing such as inflammation. Conversely, fasting suppresses mTOR activity. That promotes autophagy, a phenomenon in which cells clear out their accumulated crud, which is reckoned lifespan-enhancing. Moreover, both substances also have the advantages of having undergone safety trials as part of approval for their on-label uses, and of being off-patent, and therefore cheap. Being off-patent, however, cuts both ways. It means commercial sponsors for human clinical trials are hard to find, since they cannot monopolise sales. As a result the Targeting Ageing with Metformin (TAME) trial, a proposal sponsored by the American Federation for Aging Research, a charity, and approved by the Food and Drug Administration in 2015, remains in abeyance for lack of funds. Rapamycin, by contrast, has been tested in what is known as the PEARL (Participatory Evaluation of Ageing with Rapamycin for Longevity) trial, which began in July 2020. But this found no strong evidence that it worked. Animal tests have proved more definitive. The new paper, published in Aging Cell by Edward Ivimey-Cook of Glasgow University and his colleagues, gathers all the vertebrate-trial evidence that the authors could find. This amounts to 167 studies on eight species, ranging from fish to monkeys. The answers seem clear-cut. To no one's surprise, calorie restriction works. So, to a pretty-much equal extent, does rapamycin. But metformin does not. That is a blow to those, their number unknown but probably amounting to thousands, who have twisted their doctors' arms to get an off-label prescription of it for life extension. But it is a boost to those who have opted for rapamycin. These include Vinod Khosla, one of Silicon Valley's best-known venture capitalists, and, until recently, Bryan Johnson, another Californian techie, who has made a second career out of his quest for immortality. Mr Johnson, however, dropped rapamycin in 2024 because of its side-effects (abnormal lipid and glucose levels, elevated heart rate and increased risk of skin infection). All of which is interesting. But for mere mortals who want a long and healthy life without the risk of rapamycin's side-effects the advice remains the same: eat wisely, drink moderately, exercise regularly, sleep well. And stub that cigarette out. Curious about the world? To enjoy our mind-expanding science coverage, sign up to Simply Science, our weekly subscriber-only newsletter. © 2025, The Economist Newspaper Limited. All rights reserved. From The Economist, published under licence. The original content can be found on
Associated Press
28-03-2025
- Business
- Associated Press
PEARL Named The Official Ball of the PLL & WLL
New York, March 28, 2025 (GLOBE NEWSWIRE) -- NEW YORK — The Premier Lacrosse League (PLL) powered by Ticketmaster and the Maybelline Women's Lacrosse League (WLL) announced on March 20th that PEARL has been named the Official Ball Partner of both professional leagues. The multi-faceted partnership also extends to PLL Play, the leagues' youth lacrosse development platform. The collaboration marks a significant milestone as PEARL becomes an inaugural equipment partner of the recently formed WLL, underscoring both organizations' commitment to providing elite equipment for the sport's top athletes. 'We're thrilled to welcome PEARL as the Official Ball Partner of the PLL, WLL, and PLL Play,' said Mike Rabil, Co-Founder and CEO of the PLL. 'This partnership represents our dedication to providing our athletes with the highest quality products available. PEARL's innovative approach to ball design, look and feel aligns perfectly with our commitment to elevate the game at every level.' PEARL has collaborated with both leagues to develop a custom ball featuring the brightest on-field colors ever used in the PLL and WLL. The enhanced visibility benefits both players during competition and fans following the action, further improving the viewing experience across broadcasts and in-stadium. 'We're thrilled that PEARL is partnering with the PLL, WLL, and PLL Play,' said Erin Hanson, Founder and CEO of Guardian Sports. 'We will be providing the best USA-made lacrosse balls to the top athletes in the world. PEARL being chosen by the PLL is a significant achievement for our company, and we are excited to bring an improved playing and viewing experience for players and fans alike. We hope this partnership will not only provide a better product on the field but also encourage fans to try the best ball on the market.' Guardian Sports, manufacturers of PEARL, is a leader in developing innovative safety solutions for athletes, with a special focus on their revolutionary PEARL lacrosse balls. PEARL lacrosse balls are designed to provide a safer and more durable playing experience. As the only manufacturer of lacrosse balls in the USA, PEARLs are re-engineered with cutting-edge technology to never grease or harden, staying in spec and outlasting the competition. In addition to the PLL, WLL and PLL Play, PEARL is the Official Ball of the NCAA Men's and Women's Lacrosse Championships and the MCLA. The partnership will also support PLL Play initiatives, helping to grow the game at the youth level by providing access to professional-grade equipment for developmental programs across the country. The custom PEARL balls made their debut at the Lexus Championship Series, and will be on field when the 2025 PLL season begins on May 30 in Albany, NY. To view the 2025 PLL season schedule and purchase tickets, visit About the Premier Lacrosse League The Premier Lacrosse League (PLL) powered by Ticketmaster is a men's professional lacrosse league in North America, composed of eight teams rostered by the best players in the world. Co-founded by lacrosse superstar, philanthropist, and investor Paul Rabil and his brother, serial entrepreneur and investor, Mike Rabil, the PLL is backed by an investment group composed of Joe Tsai Sports, The Chernin Group, Arctos, Brett Jefferson Holdings, The Raine Group, Creative Artists Agency (CAA), The Kraft Group, Bolt Capital and other top investors in sports and media. The PLL is distributed through an exclusive media rights agreement with ABC, ESPN, ESPN2, and ESPN+. The PLL was named 2023 Best Place to Work in Sports, and 2020 Sports Breakthrough by the Sports Business Journal, and recognized as a 2021 Best Employer in Sports by Front Office Sports. For more on the league, visit and follow on social media: Instagram (@PLL), Twitter (@PremierLacrosse), Facebook (@PremierLacrosseLeague), YouTube ( and TikTok (@pll). About the Maybelline Women's Lacrosse League The Maybelline Women's Lacrosse League (WLL) is a women's professional lacrosse league in North America, composed of four teams rostered by the best players in the world. Launched in November 2024 by the Premier Lacrosse League (PLL), the WLL represents the league's biggest investment in women's lacrosse to date. The PLL is co-founded by lacrosse superstar, philanthropist, and investor Paul Rabil and his brother, serial entrepreneur and investor, Mike Rabil. The PLL is backed by an investment group composed of Joe Tsai Sports, The Chernin Group, Arctos, Brett Jefferson Holdings, The Raine Group, Creative Artists Agency (CAA), The Kraft Group, Bolt Capital and other top investors in sports and media. The WLL and PLL are distributed through an exclusive media rights agreement with ESPN. For more on the league, visit and follow on social media: Instagram (@WLL), Twitter (@WLacrosseLeague), Facebook (@WomensLacrosseLeague), and TikTok (@WomensLacrosseLeague). About PEARL PEARL lacrosse balls are manufactured by Guardian Sports located in Peachtree Corners, Georgia. Erin and Lee Hanson started Guardian in 2011 with one goal in mind – innovating equipment to better serve athletes. Their 25+ years of experience owning and operating a material science and technology company has enabled them to create multiple pieces of sports equipment that better protect athletes. Guardian are the manufacturers of the Guardian Cap, PEARL lacrosse balls, LOOP 7v7 headgear, and Bio-based Infill. In 2015, Guardian re-engineered the lacrosse ball and introduced the first PEARL lacrosse ball to address the greasing issue with rubber lacrosse balls that took lacrosse balls out of spec by the time of play. Guardian became the only manufacturer of lacrosse balls in the USA and introduced the PEARL X, a greaseless game day ball that never hardens and stays in spec. The team expanded the PEARL line by adding LT, a textured ball, NX, a no-bounce practice ball, and DUAL X, the first two-toned lacrosse ball. PEARL is currently the Official Ball of MCLA, NCAA Men's and Women's Championships, the PLL, WLL, and PLL Play. PEARL continues to innovate the lacrosse ball and create products that are reliable, consistent, and innovative. For more on PEARL, visit shop and follow on social media: Instagram (@Pearl_Lacrosse), Twitter (@Pearl_Lacrosse), Facebook (@PearlLacrosse), and TikTok (@Pearl_Lacrosse).
